Navigation Links
Duska Therapeutics Obtains Standard & Poor's Listing
Date:6/26/2008

LA JOLLA, Calif., June 26 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA.OB) ("Duska" or the "Company") announced today that its company information is available via Standard & Poor's Corporation Records Listing Program. As part of the program, a full description of Duska Therapeutics is published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 38 states under the Blue Sky Laws. Standard Corporation Records is available in print, on CD-ROM, and via the Web at http://www.netadvantage.standardandpoors.com as well as through numerous electronic vendors.

The Duska Therapeutics corporate information now available through the Records Listing Program includes an in-depth description of the Company's business operations, share price, dividend history, shares outstanding, company's financial position, earnings, and full income statement and balance sheet.

Earlier this month Duska Therapeutics announced it has been granted an exclusive worldwide license from Duke University and Johns Hopkins University to develop and commercialize their rights to a portfolio of investigational cardiovascular drugs designed to correct nitric oxide and redox disequilibrium in the failing heart and cardiovascular system. The lead candidate is expected to enter Phase II clinical trials later this year.

About Duska Therapeutics, Inc.

Duska Therapeutics, Inc., in La Jolla, California, is a biotechnology company focused on the development of medical products based on adenosine triphosphate and nitric oxide. Duska owns or has exclusive licensing rights to proprietary medical products that are in various stages of development for the treatment and diagnosis of certain cardiac arrhythmias, treatment of heart failure, treatment of chronic obstructive pulmonary disorder, and improvement of sperm motility. For more information, visit http://www.duskatherapeutics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Duska are forward-looking statements such as the lead candidate is expected to enter Phase II clinical trials later this year. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Duska on the date hereof. Duska undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.


'/>"/>
SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building cooking event ... companies around the world, such as Illumina, HP and Qualcomm, and is ranked #1 in ... popularity is due to its new team building format, a way for teams to not ...
(Date:3/23/2017)... March 23, 2017  SeraCare Life Sciences, ... in vitro diagnostics manufacturers and clinical laboratories, ... first multiplexed Inherited Cancer reference material ... by next-generation sequencing (NGS). The Seraseq™ Inherited Cancer ... input from industry experts to validate the ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... selected by the Connecticut Technology Council (CTC) as a 2017 Women of Innovation® ... annual Women of Innovation Awards Dinner. , The dinner recognizes women accomplished in ...
(Date:3/23/2017)... York , March 23, 2017 According ... plasma products and derivatives market is fragmented due to the presence of ... such as Proliant, Thermo Fisher , and Sigma-Aldrich, compete with ... these three companies, collectively, held more than 76% of this market ... As ...
Breaking Biology Technology:
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , a ... globally, announces significant enhancements to new and core technologies ... New products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity ... technology provides the fastest and most accurate capture software ...
(Date:2/28/2017)... 27. Februar 2017  EyeLock LLC, ein marktführendes Unternehmen ... erstklassige biometrische Lösung zur Iris-Erkennung auf der ... LTE auf dem Mobile World Congress 2017 ... in Halle 3, Stand 3E10, vorstellen. ... Qualcomm Haven™ – eine Kombination aus Hardware, ...
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... and Reentry. "Too often, too many ... and county jails are trying to tackle this ... and friends and family members. While significant steps are ...
Breaking Biology News(10 mins):